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AbSTrACT
Interstitial lung diseases (ILDs) are a heterogeneous 
group of conditions, with a wide and complex variety 
of imaging features. Dificulty in monitoring, treating 
and exploring novel therapies for these conditions 
is in part due to the lack of robust, readily available 
biomarkers. Radiological studies are vital in the 
assessment and follow-up of ILD, but currently CT 
analysis in clinical practice is qualitative and therefore 
somewhat subjective. In this article, we report on the 
role of novel and quantitative imaging techniques 
across a range of imaging modalities in ILD and 
consider how they may be applied in the assessment 
and understanding of ILD. We critically appraised 
evidence found from searches of Ovid online, PubMed 
and the TRIP database for novel and quantitative 
imaging studies in ILD. Recent studies have explored 
the capability of texture-based lung parenchymal 
analysis in accurately quantifying several ILD features. 
Newer techniques are helping to overcome the 
challenges inherent to such approaches, in particular 
distinguishing peripheral reticulation of lung 
parenchyma from pleura and accurately identifying 
the complex density patterns that accompany 
honeycombing. Robust and validated texture-based 
analysis may remove the subjectivity that is inherent 
to qualitative reporting and allow greater objective 
measurements of change over time. In addition to 
lung parenchymal feature quantiication, pulmonary 
vessel volume analysis on CT has demonstrated 
prognostic value in two retrospective analyses and 
may be a sign of vascular changes in ILD which, to 
date, have been dificult to quantify in the absence of 
overt pulmonary hypertension. Novel applications of 
existing imaging techniques, such as hyperpolarised 
gas MRI and positron emission tomography (PET), 
show promise in combining structural and functional 
information. Although structural imaging of lung tissue 
is inherently challenging in terms of conventional 
proton MRI techniques, inroads are being made with 
ultrashort echo time, and dynamic contrast-enhanced 
MRI may be used for lung perfusion assessment. 
In addition, inhaled hyperpolarised 129Xenon gas 
MRI may provide multifunctional imaging metrics, 
including assessment of ventilation, intra-acinar gas 
diffusion and alveolar-capillary diffusion. PET has 
demonstrated high standard uptake values (SUVs) 
of 18F-luorodeoxyglucose in ibrosed lung tissue, 
challenging the assumption that these are ’burned 
out’ and metabolically inactive regions. Regions 
that appear structurally normal also appear to have 
higher SUV, warranting further exploration with future 
longitudinal studies to assess if this precedes future 
regions of macroscopic structural change. Given 
the subtleties involved in diagnosing, assessing and 
predicting future deterioration in many forms of 
ILD, multimodal quantitative lung structure-function 
imaging may provide the means of identifying novel, 
sensitive and clinically applicable imaging markers 
of disease. Such imaging metrics may provide 
mechanistic and phenotypic information that can help 
direct appropriate personalised therapy, can be used 
to predict outcomes and could potentially be more 
sensitive and speciic than global pulmonary function 
testing. Quantitative assessment may objectively 
assess subtle change in character or extent of disease 
that can assist in eficacy of antiibrotic therapy or 
detecting early changes of potentially pneumotoxic 
drugs involved in early intervention studies.
InTroduCTIon
Imaging plays a key role in the diagnosis and assess-
ment of interstitial lung disease (ILD). A multi-
disciplinary team with expertise in ILD can often 
reach a reliable diagnosis based on clinical findings 
and radiology alone, as exemplified by the Joint 
Consensus International Societies Statement on the 
classification of idiopathic interstitial pneumonias.1 
In practice, radiological examinations are qualita-
tively interpreted with an inherent degree of subjec-
tivity. However, ILD features such as honeycombing 
are often subtle and may be mimicked by other 
conditions, leading to interobserver disagreement 
in their presence and extent.2 Thus, interest exists 
in developing quantitative and novel imaging tools. 
We provide a commentary on the recent develop-
ments in novel imaging techniques in ILD, with a 
focus on quantitative high-resolution CT (HRCT) 
and new techniques from MRI and positron emis-
sion tomography (PET).
MeThodS
Literature searches were performed using the 
Medline database via Ovid online portal at the 
University of Sheffield (UK) and cross-referenced 
with identical search terms on PubMed and TRIP 
database (both web based and open access). Two 
reviewers (NDW and JAE) independently performed 
the search and identified articles for inclusion. Only 
human studies since 1998 with n>1 were included. 
Studies were assessed on methodological approach, 
bias and quality using the Scottish Intercollegiate 
Guidelines Network (SIGN) checklist. In case of 
disagreement about inclusion, an arbitrator (JMW) 
made the final decision and acted as guarantor. The 
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and Meta-Analyses flow diagram and search terms are provided 
in two online supplements.
QuAnTITATIve IMAgIng
Computed tomography
HRCT is a highly sensitive imaging tool for the assessment of 
macrostructural changes in ILD. In the era of multidetector CT 
scanners, volumetric protocols acquired during inspiration are 
preferred to non-contiguous slices due to enhanced sensitivity to 
spatially heterogeneous ILD features.3 HRCT plays a key role in 
identification of the pathological phenotype of ILD, and typical 
imaging features are well recognised in international consensus 
guidelines.1 Even so, disagreement on presence or quantifi-
cation of disease severity between independent radiologists is 
common.2 4 5 Semiquantitative CT scoring analysis by expert 
radiologists may provide prognostic insight,6 but there remains 
no standard method for scoring radiological extent or severity. 
Quantification of overall lung histogram features, regional CT 
density changes, parenchymal texture features and other assess-
ments by advanced algorithms including unsupervised machine 
learning and deep learning approaches to image analysis have 
the potential to standardise and develop the role of HRCT in 
ILD.
Lung density analysis
HRCT density measurements have been used to quantitatively 
assess lung structure in a range of respiratory conditions, most 
prominently in emphysema.7 The CT density histogram of 
QRUPDOOXQJWLVVXHLVSHDNHGDWDSSUR[LPDWHO\ï+RXQVILHOG
units and is left-skewed. An increase in the amount of soft 
tissue, due to fibrosis, will increase mean lung density (MLD) 
and decrease the histogram kurtosis and skew.8 Whole-lung 
CT metrics, such as MLD,8 or lowest fifth percentile of the 
lung density histogram,9 correlate with physiological measures 
of severity, and change with disease progression. Although 
several studies have explored the relationship between density 
histogram metrics and ILD outcomes,1114 reducing quantitative 
regional information from highly sensitive imaging to global 
summary measurements sacrifices the richness of the imaging 
data. Global measures are also confounded by other features 
such as air trapping in hypersensitivity pneumonitis (HP) and 
parenchymal destruction in combined pulmonary fibrosis and 
emphysema (CPFE) syndrome.
The ability of lung density analysis to differentiate between 
usual interstitial pneumonia (UIP) pattern fibrosis/idio-
pathic pulmonary fibrosis (IPF) and other types of ILD is debat-
able. Do et al demonstrated significant differences in kurtosis 
and skewness between 28 patients with non-specific interstitial 
pneumonia (NSIP) and 32 patients with UIP pattern of fibrosis.15 
However, two studies by Sverzellati et al did not identify a signif-
icant difference in kurtosis, skewness and mean lung attenuation 
between UIP pattern fibrosis/IPF patients and patients with HP 
and/or unclassifiable idiopathic interstitial pneumonia.16 17
Texture-based analysis and machine learning
Texture-based analysis and computer vision-based approaches 
can be applied to imaging data to characterise, model and 
process imaging features, simulating human visual perceptual 
and learning processes using two dimensional or volumetric 
classification algorithms. Focal texture analysis can potentially 
evaluate both global and regional information, generating quan-
titative metrics. The texture features can allow for both density 
and morphological assessment that can provide a means of 
determining the type of abnormality (such as emphysema vs 
honeycombing vs cysts), the severity (fine vs coarse reticulation) 
and extent of disease that correlates with expert radiologist 
assessment.18
The adaptive multiple feature method (AMFM) is a lung 
texture analysis software that has been designed to recognise 
HRCT patterns. AMFM uses a combination of 26 different 
mathematical features describing regional density patterns, 
along with a Bayesian classifier to recognise and quantify the 
volume occupied by a variety of radiological patterns. This 
can distinguish emphysema from fibrosis, identify ground glass 
opacification (GGO) and normal lung.1921 The two-dimen-
sional AMFM appeared relatively unsuccessful in identifying 
honeycombing due to the complex appearance of high and 
low attenuation values in these regions.22 Further work on the 
AMFM allowed three-dimensional (3D) assessment.23 Sensi-
WLYLW\ DQG VSHFLILFLW\ IRU DXWRPDWHG LGHQWLILFDWLRQ ZDV 
IRU HPSK\VHPDDQG FRQVROLGDWLRQ DQGDQG UHVSHF-
tively, for honeycombing.23 AMFM was retrospectively applied 
to the HRCT scans in a large clinical trial of patients with 
IPF, where extent of GGO was independently associated with 
disease progression.21 Boehm and colleagues demonstrated that 
combining densitometric and topological information allowed 
automated analysis to reproduce radiologists ratings on disease 
VHYHULW\ UDQJLQJ IURP  DJUHHPHQW LQ ILEURWLF UHJLRQV WR
LQQRUPDOUHJLRQV24
Asakura et al created the Gaussian Histogram Normalized 
Correlation (GHNC) system, which uses local histograms and 
the degree of CT attenuation to separate the lungs into five cate-
gories.25 Using GHNC, Iwasawa et al showed a smaller increase 
in fibrosis score and F-pattern volume on the follow-up CTs in 
38 patients with IPF treated with pirfenidone compared with 
 DJHPDWFKHG FRQWUROV ZLWK ,3)5 There were no significant 
differences in the sensitivity, specificity and accuracy between 
GHNC analysis, visual CT score and radiologist interpretation.
Defining lung regions manually is time consuming, therefore 
automated segmentation of lung fields may allow more wide-
spread use of quantitative CT. Pathology adjacent to the pleural 
surface can be problematic, as ILD features may be similar in 
appearance to soft tissue.  Korfiatis et al described how 
a support vector machine can be used to perform an iterative 
neighbourhood labelling process, whereby lung voxels in the 
border regions of the lung are iteratively rechecked against 
labelled voxels to refine the lung border, thus improving delin-
eation of lung tissue.27
Unsupervised feature leaning paradigms, such as data-driven 
textural analysis (DTA), are able to use clustering analyses to find 
common features from a collection of raw images. Humphries 
et al used the DTA algorithm to analyse 55 CT scans from the 
IPFnet ACE study, identifying consistent low-level pixel patterns 
and thus generating a dictionary of ILD elements. These were 
compared with 35 CTs from the COPDGene study as examples 
of non-fibrotic lungs. The derived fibrosis score (fibrotic regions 
of interest (ROIs)/total ROI) correlated with pulmonary function 
WHVWV 3)7V LQ  SDWLHQWV ZLWK ,3) DW EDVHOLQH DQG GHFUHDVH
in FVC at follow-up was associated with an increase in DTA 
fibrosis score in 72 follow-up patients.28
Computer Aided Lung Informatics for Pathology Evaluation 
and Rating (CALIPER) is an image analysis tool that uses both 
3D histogram features within a regional voxel and morpho-
logical analysis to characterise HRCT data. The classifier was 
developed based on consensus radiologist determination of 
parenchymal features of voxels randomly selected from training 
images with histopathologically confirmed disease for a variety 
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of lung parenchymal pathologies and control subjects2931 from 
the Lung Tissue Research Consortium.32 In retrospective clin-
ical assessment of 55 patients with IPF, CALIPER-measured 
ILD changes including percent ILD, total ILD volume and total 
reticulation volume were associated with survival at multivariate 
analysis.33 An example output from CALIPER in a patient with 
UIP is shown in figure 1.
veSSeL QuAnTIfICATIon
Jacob et al report automatic segmentation of the pulmonary 
vasculature, defining quantitative output in terms of vessel 
cross sectional area.34 35 The sum of pulmonary vessel volume 
(PVV) not only correlated with visually and quantitatively 
assessed extent of disease, but when combined with physiolog-
ical parameters, prognosticated better than the Gender, Age , 
and Physiology (GAP) score.34,QSDWLHQWVZLWKFRQQHFWLYH
tissue disease ILD (CTD-ILD), PVV outperformed physiological 
indices and visual CT scores as predictors of mortality.35 In IPF, 
upper zone CALIPER vessel-related structure variables were 
IRXQGWREHWKHVWURQJHVWSUHGLFWRUVRIGHDWKDQGRU)9&
decline at 12 months.36
As the volumetric assessment of the size and morphology of 
branching vascular structures is extremely difficult for a radiolo-
gist, this novel metric highlights the potential utility of quantita-
tive measures that do not have a current visual or morphological 
correlate in the radiology lexicon. Additional machine learning 
or deep learning techniques may elucidate features that are not 
perceptible nor reproducibly assessed by humans.
LIMITATIonS
Several issues exist in the standardisation of quantitative CT 
metrics. Multicentre trials are confounded by differences in 
scanner equipment and protocols. Choice of reconstruction 
algorithm influences image resolution and density histogram 
parameters. In particular, a high-frequency reconstruction algo-
rithm reduces per pixel histogram skewness and kurtosis.37 
Regular quality assurance by scanning phantoms at all collabo-
rating sites is not always feasible.11 Standardisation of the image 
density to tracheal air density is plausible,38 but density varies 
throughout the trachea. Chong et al have reported on a novel 
feature selection scheme that prioritises recognition features 
robust to variations in apparent lung density, reporting enhanced 
performance in correctly identifying key disease features in 
ILD.39 In spite of such obstacles, Iwisawa and colleagues reported 
excellent agreement in automated CT pathology features across 
different scanners and sites using the GHNC analysis technique.
Lack of standardisation of inspiration level during CT acquisi-
tion may also lead to differences in density. Previous data suggests 
LQVSLUDWLRQ WR D OXQJ YROXPH  RI YLWDO FDSDFLW\ \LHOGV WKH
most reproducible density results.41 However, spirometric gating 
is not routinely available in most centres, and some researchers 
report adequate reproducibility without spirometric standardi-
sation of inspiratory effort.12 Comorbidities such as heart failure 
or exogenous factors such as contrast media are likely to affect 
the overall lung density, but quantitative analysis of their impact 
is lacking.
CT SuMMAry
Recent significant advances in quantitative CT have been made 
in semiautomated lung segmentation and greater success in the 
automated identification of honeycombing using texture anal-
ysis, alongside new means of assessing the associated pulmonary 
vascular changes. While global physiological indices of disease 
progression such as PFTs are affected by comorbidities such 
as emphysema, ideally quantitative CT should objectively and 
accurately measure structural interstitial change as a standalone 
parameter, enabling effective analysis of treatment response or 
objective assessment of disease progression. At present, these 
figure 1 Representative results from the quantitative analysis of CALIPER. Each row (A–C) and (D–F) correspond to the two timepoints from one 
patient with usual interstitial pneumonia. The individual voxels of the lung regions in the original sections (A and D) are classiied and colour coded 
into one of the classes of visible abnormalities (B and E). Three-dimensional maximum feature projections are also shown (C and F). Reproduced with 
permission from European Respiratory Society.33 CALIPER, Computer Aided Lung Informatics for Pathology Evaluation and Rating.
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methods require varying degrees of manual input, which will 
need to be automated before rolling out the technology for use 
in routine clinical practice.
Magnetic resonance imaging
Acquisition of lung MRI is challenging due to a number of 
factors, including low proton density of lung tissue, multiple air 
tissue interfaces causing magnetic field inhomogeneity, rapid MR 
signal relaxation and respiratory and cardiac motion. However, 
proton MRI methods such as ultrashort echo time (UTE) 
offer the possibility to image ILD structural changes at greater 
resolution, and contrast-enhanced imaging offers a means of 
pulmonary perfusion assessment. In addition, MRI of inhaled 
hyperpolarised gases offer the ability to assess changes in lung 
ventilation,42 microstructure43 44 and gas exchange assessment.45
ProTon denSITy, T1 And T2 MrI
Established proton MRI techniques such as 3D gradient echo 
and balanced steady-state free precession demonstrate reason-
able sensitivity to fibrotic regions of lung tissue, although qualita-
tive structural assessment is undoubtedly inferior to CT.46 Subtle 
abnormalities such as thickening of lobar septae are difficult to 
appreciate on MRI.47 In a retrospective study of CT and MRI in 
systemic sclerosis (SSc) associated ILD, extent of disease on MRI 
and CT correlated well, but MRI underscored more extensive 
disease.48 More recently, UTE imaging with radial acquisition of 
k-space, such as that shown in figure 2, has enabled reductions 
RIHFKRWLPHWROHVVWKDQVWKXVPLQLPLVLQJ7GHSKDVLQJ
signal losses resultant from magnetic field inhomogeneity at 
airtissue interfaces. With 3D free breathing acquisition, these 
methods provide improved structural image quality and reso-
lution at the cost of motion artefact at the lung bases and long 
acquisition time, as demonstrated in figure 2.49 With the intro-
duction of UTE MRI, the diagnostic accuracy of proton MRI in 
ILD has been found to be comparable with that of HRCT.
Regional T1 and T2 relaxation time characteristics of lung 
tissue may discriminate ILD pathology. Stadler et al demon-
strated that the T1 of fibrotic lung parenchyma is significantly 
longer than emphysema, but these T1 values were heavily influ-
enced by lung inflation state.52 Buzan et al observed that GGO, 
reticulation and honeycombing have inherently different T2 
relaxation times in 12 patients with NSIP or UIP.53 A larger study 
by the same author published 2 years later confirmed a strong 
positive correlation between T2 relaxation and proton density 
LQ 16,3 U  S EXW WKLV FRUUHODWLRQ ZDV ZHDN LQ
8,3SDWWHUQRIILEURVLVU S 54 In the NSIP group, 
those with suspected inflammatory activity had statistically 
significant increased T2 relaxation times when compared with 
those with suspected stable disease. Unfortunately, the difference 
in T2 relaxation times between UIP and NSIP was not statis-
tically significant, thereby suggesting that T2-weighted proton 
MRI is not a reliable method to differentiate between these two 
important patterns of pulmonary fibrosis.
MR elastography (MRE) is a method of measuring tissue stiff-
ness by measuring acoustic shear wave propagation. A recent 
study by Marinelli et al used MRE to quantify a difference in 
topographical distribution of shear stiffness between 15 patients 
with ILD (including eight with IPF) compared with 11 healthy 
volunteers.55 They found that with increasing transpulmonary 
pressure (from residual volume to total lung capacity), the lung 
figure 2 Axial and sagittal reformats of the high-resolution CT (HRCT) (A), three-dimensional ultrashort echo time (3D UTE) (B) and the second 
echo of the 3D UTE sequence (C). Although honeycomb change is visualised in the UTE image, HRCT images show higher spatial resolution. The 
structural abnormality is not well visualised in the second echo images. Reproduced with permission from John Wiley and Sons.49
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stiffness increased. It would be interesting to see if future studies 
using MRE in ILD can demonstrate this as a valuable diagnostic 
tool in monitoring of disease progression and providing dynamic 
lung function data.
oxygen-enhanced proton MrI
Oxygen-enhanced MRI uses the paramagnetic (T1-shortening) 
effect when molecular oxygen dissolves in tissue water and blood 
in the lungs. By acquiring images using a paradigm of alternating 
inhaled oxygen at room air concentration and high flow oxygen 
and thereafter subtracting the images, maps of T1-shortening 
are derived. Müller et al found a statistically significant differ-
ence in the signal intensity (SI) changes and SI slopes between 17 
patients with various pulmonary diseases (including 12 with IPF 
and 1 with HP) and 11 healthy volunteers.56 A strong correla-
tion was seen between the SI slope values and diffusing capacity 
of the lungs for carbon monoxide (DLCO), but the correlation 
was weak between SI change values and DLCO for the section 
selective inversion pulse. Ohno et al demonstrated enhancement 
changes in patients with CTD-ILD versus healthy controls.57 
Molinari et al used percentage of oxygen-activated pixels 
2$3DVDTXDQWLWDWLYHPHWULFGHPRQVWUDWLQJDFRUUHODWLRQRI
2$3ZLWK'/&2LQDFRKRUWRISDWLHQWVZLWKYDULRXVIRUPVRI
ILD.58 Given that the oxygen environment is dependent on both 
local ventilation and perfusion, separating the contribution of 
each is a significant current challenge.
hyperpolarised gas MrI
Hyperpolarised gas MRI exploits the signal enhancement avail-
able by the technique of spin exchange optical pumping of 
helium (3He) or xenon (129Xe). These atoms have spin ½ and can 
thus be imaged with conventional MRI methods with dedicated 
radio frequency coils.59 The hyperpolarised gas is prepared in a 
pure state or mixed with nitrogen or oxygen and inhaled by the 
patient, who holds their breath for several seconds during acqui-
sition. This technique is reportedly well tolerated in patients 
with various lung diseases.
While 3He is insoluble in lung tissue, 129Xe does not remain 
exclusively in the airways but crosses the alveolar interstitium 
into capillary blood. Diffusion limitation can be probed with MR 
spectroscopic techniques, which take advantage of the unique 
chemical shift of 129Xe in gaseous, aqueous (tissue and plasma 
[TP]) and red blood cell (RBC) environments. The RBC peak 
signal was reduced in comparison with the TP signal in patients 
with IPF versus healthy volunteers, suggesting that spectroscopic 
approaches may provide a viable biomarker of interstitial thick-
ening.45 Indeed, measures of 129Xe gas exchange correlated with 
DLCO in two small cohorts of patients with IPF and SSc-asso-
ciated ILD.45 61 These spectroscopic techniques can be extended 
to provide regional information in the form of ratios of RBC/TP 
potentially forming the basis of regional gas exchange mapping 
of the lungs.62 63 Wang et al demonstrated that these signals 
showed weak correlation with qualitative CT and semiquantita-
tive CT scores in a cohort of subjects with IPF but good correla-
tion with PFTs.64 Weatherley et al recently showed that the ratio 
of the RBC/TP peaks in patients with IPF is highly sensitive to 
FKDQJHZKHQVFDQQHGDWPRQWKPRQWKDQGPRQWKLQWHU-
vals when compared with FVC and DLCO.65 These 129Xe MRI 
measures of gas exchange provide a novel means of functional 
assessment of ILD. Example spectra and dissolved phase imaging 
are shown in figure 3 and figure 4. However, changes in 129Xe 
MR spectroscopy metrics are likely to result from both inter-
stitial thickening and changes in pulmonary haemodynamics, 
as a recent dual case report suggests and the influence of each 
requires further investigation.66
Diffusion-weighted MRI of HP gases enables quantification of 
the Brownian motion of these gases in the acinus by mapping of 
the apparent diffusion coefficient (ADC) of the gas. The ADC is 
reflective of acinar airway integrity and microstructural length 
scales in pulmonary disorders, such as emphysema.44 Altered 
ADC has been reported in a small cohort of patients with 
pulmonary fibrosis, indicating a disruption of the acinar micro-
structure, but it is not clear if these changes precede structural 
changes evident on CT.43
dynamic contrast-enhanced MrI
MR contrast uptake parameters using dynamic contrast-en-
hanced (DCE) MRI provide a means of pulmonary haemo-
dynamic assessment. Tsuchiya et al illustrated that pulmonary 
arterial flow was slower in a cohort of patients with ILD than in a 
group of volunteers without lung disease.67 However, pulmonary 
arterial flow as a single measure did not demonstrate correlation 
with disease severity. In a study of patients with CPFE, mean 
transit time (MTT) through the lung was prolonged compared 
with healthy controls.68 MTT also correlated with pulmonary 
artery pressure and pulmonary vascular resistance, measured by 
right heart catheterisation. Example transit time images along-
side representative anatomical CT slices in patients with IPF are 
shown in figure 5. Metrics such as pulmonary blood volume 
variation during the cardiac cycle may provide early warning of 
pulmonary haemodynamic changes in ILD or impending pulmo-
nary hypertension.69
Early and late contrast enhancement features may also help 
differentiate inflammation from fibrotic-predominant pathology. 
figure 3 Example of whole-lung spectral peaks generated from hyperpolarised xenon magnetic resonance spectroscopy. Figure part A is generated 
from a healthy volunteer. The red blood cell (RBC) peak is relatively preserved. In mild (B) and severe (C) IPF, with gender, age, and physiology (GAP) 
scores 1 and 3, respectively, the RBC peak is diminished with respect to the tissue/plasma peak, suggesting a diminishment in gas transfer eficiency 
of the lung.
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Yi and colleagues dichotomised biopsy specimens from 26 
patients with UIP into inflammation or fibrosis predominant, 
finding that early T1 enhancement was more likely to be asso-
ciated with inflammation. Mirsadraee et al also demonstrated 
the feasibility of pre-contrast and post-contrast T1 mapping 
of IPF.71 ,QSDWLHQWVZLWK ,3) FRQWUDVWXSWDNHZDVGHOD\HG
FRPSDUHGZLWKKHDOWK\YROXQWHHUVLQFOXGLQJLQUHJLRQVZLWK
normal precontrast T1 values, suggesting that early perfusion 
changes may be detectable prior to morphological changes. 
Another study also demonstrated that late contrast-enhanced 
05,VLJQDOZDVVLJQLILFDQWO\LQFUHDVHGLQWKHOXQJVRISDWLHQWV
with IPF compared with 12 healthy volunteers.72 There was a 
strong correlation between the degree of pulmonary fibrosis on 
late enhanced MRI and HRCT.
MrI SuMMAry
Several MRI metrics from conventional, oxygen-enhanced, 
hyperpolarised gas and DCE MRI are under exploration. A 
number of promising methods are available; however, assess-
ment of the reproducibility of derived metrics and longitudinal 
observation in human participants with ILD is required to assess 
their suitability as accurate markers of disease. Functional MRI 
metrics will also benefit from direct comparison with structural 
imaging approaches through image registration techniques. 
Novel molecularly sensitive MR techniques such as collagen-tar-
geted chelated MR agents,73 or acidoCEST MRI for extracel-
lular pH estimation,74 may provide further opportunities for 
novel MRI of ILD in the coming years. At present, this remains a 
research tool, but use in early phase pharmaceutical intervention 
programmes can be envisaged in the near future.
Positron emission tomography
PET is rarely clinically used in ILD. Inflammatory predominant 
and thus metabolically active ILDs provide the most intuitive 
targets for the use of 18F-fluorodeoxyglucose (FDG) PET. For 
example, Tateishi et al demonstrated that the standardised 
uptake value (SUV) of FDG correlated with lymphocyte activity 
in 22 patients with organising pneumonia,75 while PET activity 
in active and persistent pulmonary sarcoidosis is associated with 
serological evidence of inflammation and loss of pulmonary 
function.76
The role of PET in fibrotic-predominant ILD is less intuitive, 
and one may expect inflammatory-predominant conditions to 
be more metabolically active. However, Jacqelin et al identified 
18 patients with cellular and fibrotic NSIP, finding that consoli-
dation, GGO, honeycombing and reticulation showed uptake in 
DQGRIUHJLRQVUHVSHFWLYHO\77 Groves et al 
evidenced that SUV increased in IPF and that 18FDG metabolism 
appeared higher in regions of reticulation and honeycombing 
when compared with ground glass regions.78 Interestingly, there 
is also evidence of increased FDG uptake in apparently normal 
lung tissue of patients with ILD identified by visual inspection 
and CT density analysis, raising the question as to whether SUV 
is identifying subclinical disease.79
Other authors have explored the role of PET in fibrosis-predom-
inant ILD and reproducibility in IPF.81 A small study involving 
eight patients with IPF showed that over a period of 6 months, 
the decline in FVC was strongly correlated with an increase in 
maximal SUV but was not associated with the visual CT score.82 
Umeda et al demonstrated that delayed-phase 18FDG uptake 
may provide a marker of disease activity in idiopathic interstitial 
pneumonia83 and later also specifically in IPF.84 Increased late 
phase uptake was predictive of mortality on both univariate and 
multivariate analysis. Although the numbers in both studies were 
relatively small, the IPF cohort was prospectively followed up 
for a median of 29 months, with 25 deaths.84 In a larger cohort 
of 113 patients, Win and colleagues demonstrated that the target 
to background ratio, calculated by dividing the maximal SUV 
by minimal SUV, predicted mortality over a mean 29-month 
follow-up, independent of GAP score.85 Novel PET tracers and 
targets such as somatostatin receptor analogues,86 cathepsin 
protease (macrophage labelling),87 labelled leukocytes88 and type 
figure 4 Wang et al demonstrated how parametric maps derived 
from hyperpolarised xenon (129Xe) magnetic resonance spectroscopy 
may phenotype gas exchange limitation in the lung in idiopathic 
pulmonary ibrosis (IPF). In healthy lungs (A), xenon gas diffuses 
eficiently across the alveolar membrane into red blood cells 
(RBCs), resulting in signal intensities in the normal range for both 
compartments. In IPF, the interstitium is thickened, increasing xenon 
uptake in the tissue. In some regions (B, arrows), diffusion across it is 
slowed, causing RBC transfer to decrease. As the disease progresses 
(C), scarring becomes so severe that 129Xe no longer diffuses into or 
through the barrier. The authors postulated that regions depicting the 
coexistence of increased barrier uptake with preserved RBC transfer 
(D, arrow) may represent regions of early disease. Reproduced with 
permission from BMJ Publishing Group.64
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I collagen89 have shown early promise in ILD assessment and 
further reports are awaited.
PeT SuMMAry
The high SUV seen in normal lung tissue in patients with ILD 
is intriguing. Further dual-time-point studies would be useful to 
assess if these areas go on to develop appreciable fibrotic change 
on structural images, ideally using formal CT registration tools. 
Novel PET tracers are yet to be clinically assessed and although 
they are promising, the requirement on a cyclotron for on-site 
manufacture of these short-lived molecules may inhibit wide-
spread uptake.
Conclusions
Quantitative analysis of multimodal imaging is likely to play 
an increasing role for combined pulmonary structure-func-
tion assessment in many pulmonary disorders. While these 
approaches require further external validation and are not yet 
ready for routine use in clinical practice, they are likely to be 
additive to ILD assessment and may play an important role in 
diagnosis and assessing treatment response. Quantifying pulmo-
nary vessel changes may prove to be an outright novel metric 
in ILD assessment. There is great promise that both supervised 
and unsupervised approaches applied to large, well-character-
ised datasets may lead to discovery of additional meaningful 
features of ILD (radiomics or imaging biomarkers). Clustering 
techniques and machine learning may allow automated strati-
fication of patients into disease categories and risk groups and 
provide decision support that may aid in the selection of optimal 
therapy and a means to assess efficacy. MRI and PET remain 
exploratory techniques in ILD but may provide a link between 
functional and anatomical elements of disease, such as is demon-
strated by regional gas exchange in129Xe MR spectroscopy. 
Novel PET tracer agents may be used in early drug development 
programmes and indeed a study using FDG PET avidity to assess 
response to dabigatran in IPF is currently recruiting to trial ( 
&OLQLFDO7ULDOVJRYLGHQWLILHU1&7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